Glycemic Control Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to
diet and exercise to improve glycemic control in participants with Type 2 Diabetes Mellitus
(T2DM) whose blood glucose level is inadequately controlled with metformin.
This study will evaluate the efficacy of TAK-875 (25 mg and 50 mg) plus metformin compared
to placebo plus metformin and sitagliptin plus metformin on glycemic control as measured by
change from baseline in glycosylated hemoglobin (HbA1c) over a 24-week Treatment Period.
Participants completing the 24-week Treatment Period may enter an optional 80-week extension
period for a total of 104 weeks of treatment.
Due to potential concerns about liver safety, on balance, the benefits of treating patients
with fasiglifam (TAK-875) do not outweigh the potential risks.
For this reason, Takeda has decided voluntarily to terminate the development activities for
fasiglifam.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06309654 -
Home-Based Circuit Training in Overweight/Obese Older Adult Patients With Knee Osteoarthritis and Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT05460884 -
Effects of Seaweed Extract on Postprandial Response to White Bread
|
N/A | |
Completed |
NCT00576394 -
Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients
|
Phase 1 | |
Recruiting |
NCT05777746 -
The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00898534 -
Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus
|
Phase 4 | |
Recruiting |
NCT05115682 -
Circadian Rhythm and Metabolic Effects of Exercise
|
N/A | |
Completed |
NCT04994327 -
Bread Replacement - Facing the Challenge to Improve Its Quality for Better Metabolic Health
|
N/A | |
Recruiting |
NCT04332393 -
Metformin to Treat Corticosteroids-induced Hyperglycemia
|
Phase 4 | |
Recruiting |
NCT04821752 -
Environmental Toxicants Avoidance Study
|
N/A | |
Completed |
NCT06217679 -
Comparing the Effects of Different Types of Exercise on Glucose Handling
|
N/A | |
Completed |
NCT00821665 -
Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose
|
N/A | |
Terminated |
NCT04171648 -
Effect of Dry Roasted Peanuts and Boiled Peanuts on Glycemic Control
|
N/A | |
Completed |
NCT05279183 -
Assessment of Reward Responses to Erythritol Using Flavor Preference Learning
|
N/A | |
Completed |
NCT05166200 -
Glycemic Response in Adults With Type 2 Diabetes
|
N/A | |
Not yet recruiting |
NCT05644717 -
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
|
Phase 4 | |
Active, not recruiting |
NCT00283972 -
LAP-BAND Observational Cohort
|
Phase 4 | |
Completed |
NCT00460499 -
Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control
|
Phase 1 | |
Completed |
NCT00848315 -
Diabetes Management in Low-Income Hispanic Patients
|
Phase 2 | |
Completed |
NCT03983499 -
Latinos Understanding the Need for Adherence in Diabetes
|
N/A | |
Active, not recruiting |
NCT05671965 -
Effects of Oral Xylitol on Subsequent Energy Intake
|
N/A |